Functional medicine and chiropractic: A case series in Type 2 Diabetes Mellitus reversal

2011 ◽  
Vol 14 (4) ◽  
pp. 147-148 ◽  
Author(s):  
Stephanie Chaney ◽  
Tom Chaney ◽  
Paul A. Oakley
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Case Series

scholarly journals Prevalence of Type 2 Diabetes Mellitus in Hepatitis C Virus Infected Population: A Southeast Asian Study

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Muhammad Sadik Memon ◽  
Zain Islam Arain ◽  
Farukh Naz ◽  
Madiha Zaki ◽  
Suresh Kumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Demographic Data ◽  
Fasting Blood Glucose ◽  
Case Series ◽  
University Hospital

Purpose. The study was aimed to investigate the frequency of diabetes mellitus type 2 in patients infected with chronic hepatitis C virus and its association with cirrhosis.Patients and Methods. This prospective case series was conducted at Section of Gastroenterology and Hepatology, Isra University Hospital, Hyderabad, over a period of 4 months from June 2009 to October 2009. Hepatitis C virus seropositive patients who were older than 18 years, diabetic or nondiabetic, were included. Basic demographic data collected by questionnaire and laboratory investigations including fasting blood glucose levels, serum cholesterol, and liver function tests were done. A logistic regression model was used to explore the association between diabetic and nondiabetic HCV seropositives and type 2 diabetes mellitus with cirrhosis.Results. A total of 361 patients with hepatitis C were analyzed; the prevalence of type 2 diabetes mellitus in HCV patients was 31.5%. Out of the total number of the participants, 58.4% (n= 211) were cirrhotics, while 41.6% (n= 150) were noncirrhotic HCV seropositives. In multivariate analysis, cirrhotic patients appeared significantly more likely (P= 0.01) to be diabetic as compared with noncirrhotic patients (OR = 2.005, 95% CI: 1.15, 3.43).Conclusion. Advancing age, increased weight, and HCV genotype 3 are independent predictors of type 2 diabetes in HCV seropositive patients, and there is a statistically significant association of cirrhosis observed with type 2 diabetes mellitus.

scholarly journals Metformin use in patients with type 2 diabetes mellitus and chronic kidney disease: An evidence-based review

2021 ◽  
Vol 50 (2) ◽  
pp. 159-170
Author(s):  
Felicia Clara JH Tan ◽  
Seng Bin Ang ◽  
Yong Mong Bee
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lactic Acidosis ◽  
Cohort Studies ◽  
Case Series ◽  
Stage 4 ◽  
Ckd Stage ◽  
All Cause Mortality

Introduction: Practice guidelines advise caution on the use of metformin in patients with type 2 diabetes mellitus with chronic kidney disease (CKD). This review aims to examine the evidence for the benefits and risks of metformin use in patients with T2DM and CKD. Methods: The Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials and PubMed were searched; the references of selected papers were hand searched. Systematic reviews, randomised controlled trials, cohort studies, case series and case-control studies were included. The full text of selected articles was reviewed. The outcomes studied were all-cause mortality, cardiovascular complications, lactic acidosis and worsening of renal function. Recommendations were graded according to the Scottish Intercollegiate Guidelines Network system. Results: A total of 139 unique articles were identified, 14 of which met the inclusion criteria and were selected for full-text review. Four cohort studies reported an association between metformin use and improved all-cause mortality in CKD stage 4 and better. Two cohort studies reported improved cardiovascular outcomes with metformin use. Four cohort studies, 1 case series and 1 case-control study reported no significant association between metformin use and an increased risk of lactic acidosis in CKD. There is a moderate level of evidence to support reduced mortality, improved cardiovascular outcomes and a low risk of lactic acidosis with metformin use in patients with T2DM and with CKD stage 4 and above. Conclusion: Existing recommendations to restrict metformin use in diabetes patients with CKD need to be reviewed in light of emerging evidence supporting its overall benefits in these patients. Keywords: Chronic renal insufficiency, metformin, type 2 diabetes mellitus

scholarly journals DKA in patients with pre-existing type 2 diabetes mellitus related to COVID-19: a case series

2021 ◽  
Vol 2021 ◽  
Author(s):  
Anthony Ramos-Yataco ◽  
Kelly Meza ◽  
Reyna Cecilia Farfán-García ◽  
Solange Ortega-Rojas ◽  
Isaac Salinas-Mamani ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Case Series ◽  
Blood Analysis ◽  
List Type ◽  
Metabolic Complications ◽  
Arterial Blood ◽  
First Case

Summary The first case of the novel coronavirus infection (COVID-19) in Peru was reported on March 6, 2020. As of September 7, 2020, about 700 000 cases of COVID-19 resulting in 29,976 deaths have been confirmed by the Ministry of Health. Among COVID-19 patients with co-morbidities, type 2 diabetes mellitus (T2DM) has been recognized as a risk factor for severe disease. Patients with T2DM may experience diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic (HHS) if infected with the coronavirus 2 (SARS-CoV-2). Regular blood analysis including arterial blood gas is essential in monitoring the care of patients with T2DM infected with COVID-19. We report five cases of DKA in patients with underlying T2DM that presented with severe COVID-19 infection. Learning points COVID-19 may cause acute metabolic dysregulations in patients with T2DM. It is important to monitor basic metabolic panel (BMP) and arterial blood gases (ABGs) in patients with COVID-19 since metabolic complications can develop unexpectedly. Patients with T2DM develop an inflammatory syndrome characterized by severe insulin resistance and B cell dysfunction that can lead to DKA.

Interleukins and miRNAs intervene in the early stages of diabetic kidney disease in Type 2 diabetes mellitus patients

2019 ◽  
Vol 13 (18) ◽  
pp. 1577-1588 ◽  
Author(s):  
Ligia Petrica ◽  
Oana Milas ◽  
Mihaela Vlad ◽  
Adrian Vlad ◽  
Florica Gadalean ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Case Series ◽  
Diabetic Kidney ◽  
Type 2 Dm ◽  
Case Series Study

Aim: The involvement of proinflammatory interleukins (IL) in diabetic kidney disease of Type 2 diabetes mellitus (DM) patients was studied in relation to a particular miRNA profile. Materials & methods: A total of 117 patients with Type 2 DM and 11 controls were enrolled in a case series study. Serum and urinary ILs and miRNAs were assessed. Results: IL-1α correlated with miRNA21, 124, estimated glomerular filtration rate (eGFR) and negatively with miRNA125a and 192; IL-8 with miRNA21, 124, eGFR and negatively with miRNA125a, 126 and 146a; IL-18 with miRNA21, 124 and negatively with miRNA146a, 192, eGFR. Conclusion: There is an association between specific serum and urinary ILs and serum and urinary miRNAs profiles in the inflammatory response in Type 2 DM patients with diabetic kidney disease.

scholarly journals Risk of Fall among Chronic Type 2 Diabetes Mellitus Patients in Lahore: A Case Series

2021 ◽  
Vol 09 (02) ◽  
pp. 87-91
Author(s):  
Zeeshan Saeed ◽  
Shahzad Ahmed ◽  
Samreen Sadiq ◽  
Hafiz Muhammad Asim
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Case Series ◽  
Chronic Type ◽  
Risk Of Fall
Sign in / Sign up

Export Citation Format

Share Document